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Abstract 
 
 
Ca++ signaling is an important component of signal transduction pathways regulating B 
and T lymphocyte proliferation, but the functional role of Ca++ signaling in regulating 
myeloid leukemia cell proliferation has been largely unexplored. We observe that the 
activated (autophosphorylated) Ca++/calmodulin-dependent protein kinase II (CaMKIIγ) 
is invariably present in myeloid leukemia cell lines as well as in the majority of primary 
acute myelogenous leukemia (AML) patient samples. In contrast myeloid leukemia cells 
induced to terminally differentiate or undergo growth arrest display a marked reduction in 
this CaMKIIγ autophosphorylation. In cells harboring the bcr-abl oncogene, the 
activation (autophosphorylation) of CaMKIIγ is regulated by this oncogene. Moreover,  
inhibition of CaMKIIγ activity with pharmacological agents, dominant negative 
constructs  or shRNAs inhibits the proliferation of myeloid leukemia cells, and this is 
associated with the inactivation / downregulation of multiple critical signal transduction 
networks involving the MAP kinase, JAK/Stat and GSK3β / β-catenin pathways.  In 
myeloid leukemia cells CaMKIIγ directly phosphorylates Stat3 and enhances its 
transcriptional activity. Thus CaMKIIγ is a critical regulator of multiple signaling 
networks regulating the proliferation of myeloid leukemia cells. Inhibiting CaMKIIγ may 
represent a novel approach in the targeted therapy of myeloid leukemia.  
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Introduction 
 
 
     The myeloid leukemias including acute myelogenous leukemia (AML) and chronic 
myelogenous leukemia (CML) are neoplastic disorders characterized by the aberrant 
proliferation and differentiation of myeloid precursor cells. AML is a remarkably 
heterogenous disease and is associated with multiple different types of genetic mutations. 
These mutations are generally of two functional types including those which (1) interfere 
with the differentiation of myeloid precursors and (2) dysregulate the proliferation and 
viability of these myeloid precursors (1). For example AML-specific chromosome 
translocations and mutations involving the RARα (2), AML-1(3) and C/EBPα (4) genes 
interfere with  the differentiation of myeloid precursors while mutations involving 
tyrosine kinase receptors such as c-kit (5) and flt-3 (6) dysregulate their proliferation and 
viability.  Other specific signal transduction pathways that are aberrantly activated in 
AML include those involving ras/raf/MAPKinase (7),  Stat3 (8), SRC - related kinases 
(9) and PI3 kinase/Akt(10).   Similarly in  CML the oncogenic bcr-abl tyrosine kinase 
that is generated by the Ph chromosome is associated with the activation of multiple 
downstream signal transduction pathways including Stat5 (11),  MAPK (12),  PI3 Kinase 
(13) and SRC-family kinases (14).   
 
 
   The Ca++/calmodulin–dependent protein kinases (CaMKs) are ubiquitously expressed 
multifunctional Ser/Thr protein kinases that function through Ca++ signaling to regulate 
the development and activity of many different cell types (15). CaMKs include CaMKI, 
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II and IV, each of which have multiple isoforms.  A critical feature shared by members of 
the CaMK family involves the regulation of their enzymatic activity by changes in 
intracellular Ca++ concentration. Ca++ binding to the ubiquitously expressed calmodulin 
triggers a conformational change that enhances its binding to the different CaMKs. This 
binding of Ca++/calmodulin in turn triggers a conformational change in the CaMKs 
leading to activation of these enzymes.  
 
    The most widely studied of these Ca++ regulated enzymes is CaMKII, which consists 
of four homologous but distinct genes (CaMKIIα, β, γ, δ). One of the critical functional 
characteristics of CaMKII is its distinct holoenzyme structure consisting of 12 identical 
subunits(16). Activation of individual subunits of this dodecameric holoenzyme by 
Ca++/calmodulin leads to the phosphorylation of adjacent enzyme subunits at 
threonine286 (for the α isoform) or at threonine287 (for the β, γ, and δ isoforms) (17). 
This CaMKII autophosphorylation leads to increased enzymatic activity and markedly 
diminishes the requirement for Ca++/calmodulin binding to maintain enzymatic activity 
(18). Thus the autophosphorylated CaMKII is autonomous and relatively independent of 
Ca++ concentration and Ca++/calmodulin regulation.   
 
   CaMKII comprises approximately 1-2% of total brain protein, and previous studies 
have identified an important role of this enzyme in regulating neuronal cell development 
and activity (19). Other studies using pharmacological inhibitors of the CaMKs have 
indicated a role for CaMKII in regulating the cell cycle progression of cultured NIH 3T3 
fibroblasts (20, 21). In contrast studies determining the role of CaMKII in regulating 
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hematopoiesis have been relatively limited.  In T lymphocytes CaMKII is involved in 
regulating  cytokine expression (22) and TCR-triggered cell proliferation (23) as well as 
the  generation of memory T cells (24).     In previous studies we have observed that 
CaMKIIγ is the CaMKII isoform that is preferentially expressed in myeloid cells, and this 
enzyme inhibits the retinoic acid induced differentiation of myeloid leukemia cell lines 
by phosphorylating and inhibiting the transcriptional activity of the retinoic acid receptor 
(RARα) (25).  In these previous efforts we observed that CaMKII inhibitors enhance the 
differentiation of certain myeloid leukemia cell lines, but this effect was only noted in 
leukemias that were responsive to retinoic acid (25).    In the present study we extend 
these studies beyond the retinoic acid responsive myeloid leukemias and describe a 
critical and central role of CaMKIIγ in regulating the proliferation of a wide variety of 
myeloid leukemia cells. We observe that autophosphorylated CaMKIIγ is commonly 
present in myeloid leukemias.  Inhibitors of CaMKIIγ including pharmacological agents 
and dominant negative constructs inhibit myeloid leukemia cell proliferation, and this is 
associated with the inactivation of multiple signal transduction pathways including 
MAPK p44,42, Stat3/Stat5, and GSK 3β / β catenin.  Moreover, we observe that Stat3 is 
directly phosphorylated by CaMKII at Ser727. These observations highlight the 
importance of CaMKII in regulating the proliferation of myeloid leukemia cells and 
suggest that inhibiting CaMKIIγ activity may be of significant value in the targeted 
therapy of myeloid leukemia.  
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 Materials and Methods 
 
Cell lines. All leukemia cell lines are cultured at 37° in RPMI supplemented with 5% 
heat-inactivated fetal calf serum.    
 
Antibodies and Western blots.  Protein extracts, immunoprecipitations and Western 
blots were performed as previously detailed (26). Antibodies against CaMKI, CaMKIIγ, 
CaMKIV, c-myc, Stat3, Stat5, calmodulin, as well as the phosphospecific CaMKII 
(T286, 287) and phosphospecific CaMKI (T177) antibodies were from Santa Cruz 
Biotechnology. Antibodies against phospho-Stat1 (Ser727), phospho-Stat3 (Ser727 and 
Tyr 705), phospho-Stat5 (Tyr 694), phospho-p44/42 MAP kinase   (Thr202/Tyr 204), 
p44/42 MAP kinase, phospho-p38 MAP kinase (Thr 180/Tyr 182), phospho-GSK3β 
(Ser9) were from Cell Signaling Technology. Antibodies against Stat1, GSK3β, β-
catenin, PP2Ac, and cyclin D1 were from BD Biosciences.  
 
Chemicals. Different inhibitors of specific signal transduction pathways including 
AG490, Jak3 inhibitor II, PP1, PD98059, UO 126, SB 203580, wortmannin, LY 294002, 
JNK inhibitor II, raf kinase inhibitor I, pho kinase inhibitor, RO-31-8220, GÖ 6983 
,cucurbitacin I, AMP kinase inhibitor compound C, KN62, KN93 and STO609  were all 
from Calbiochem. All-trans retinoic acid (ATRA), phorbol myristate acetate (TPA), 
arsenic trioxide and SB216367 were from Sigma.  
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Patient AML and normal CD34+ samples.   Patient AML samples were obtained from 
the Childrens Oncology Group (COG) bank of AML cells. Ficoll gradient centrifugation 
was utilized to isolate mononuclear cells from bone marrow aspirates from newly 
diagnosed patients with AML. These cells consisted of > 80% blasts by morphology and 
were stored frozen under liquid nitrogen. Normal CD34+ cells were immunopurified 
from G-CSF mobilized, leukophoresed peripheral blood stem cell donors. Appropriate 
IRB approval was obtained for utilizing these patient and normal donor samples which 
are anonymized such that individuals cannot be identified.  
 
GST-fusion proteins.  The coding region of the human Stat3α gene was amplified by 
RT-PCR and subcloned into the GST fusion protein expression vector, pGEX5x.1.  The 
GST-Stat3 fusion protein was purified from bacteria extracts using glutathione-4B 
Sepharose (Amersham Biosciences).  
 
Expression vectors.  A cDNA harboring the coding sequence of amino acids 1-290 of 
CaMKIIγ was cloned into the LXSN retroviral expression vector (M28248).  Utilizing 
site-directed mutagenesis we mutated Lys43 of this construct to methionine to generate a 
kinase deficient CaMKII mutant labeled kdCaMKII.   
 
CaMKIIγ cDNA amplification and sequencing. Total cellular RNA from the leukemia 
cell lines and normal tissue was isolated by Trizol reagent (Invitrogen). First strand 
cDNA was made by the superscript amplification system (Invitrogen) with the 
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oligo(dT)12-18 primer. To determine the expression of the different CaMKIIγ isoforms we 
performed RT-PCR utilizing primers flanking the variable region of CaMKIIγ including:  
 
Sense 5’          CGTCAGGAGACTGTGGAGTGT     
Antisense  5’   TCACTG CAG CGG TGC GGC AGG  
 
To amplify and sequence the complete CaMKIIγ coding sequence the cDNA from the 
HL60 and NB4 cell lines was amplified in separate reactions with two different primer 
pairs flanking the amino terminal and COOH terminal regions of the CaMKIIγ coding 
sequence. The sequence of these primers as well as the GAPDH control primers are 
available on request. The PCR products were isolated and subcloned into the TA cloning 
vector for DNA sequencing.  
Transient transfections and luciferase assays.   K562 cells were transiently transfected 
utilizing electroporation.  5x106  cells were electroporated at 500 μF, 250 V, and  cultured 
for 24 h under standard conditions.  NIH3T3 cells were transiently transfected utilizing 
lipofectamine 2000 (Invitrogen).  Stat3 transcriptional activity was determined in K562 
cells transfected with the pSIE-tk-LUC luciferase reporter which harbors a Stat3 binding 
site (CCTTAATCCTTCTGGGAATTCTGGCT). The β-gal reporter driven by the β-
actin promoter was used as an internal control for transfection efficiency.    
CaMKIIγ RNAi constructs. Three LXSN based plasmids harboring three different 
synthetic human CaMKIIγ oligos designed to generate shRNA hairpins were constructed 
as previously detailed (25). We synthesized and inserted an additional oligo generating an 
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shRNA corresponding to human CaMIKIIγ (NM_172171) coding region (954-976) into 
the pLL3.7 lentiviral vector plasmid which harbors a GFP marker (27). These four 
plasmids were simultaneously electroporated into K562 cells which were selected in 
G418 (800 ug/ml) for 10 days. GFP+  cells from this culture were then FACS enriched 
and cell lysates subjected to Western blot analysis.  
Construction and utilization of doxycycline inducible expression vectors.  A full 
length CaMKIIγ cDNA was mutated at Lys43 to methionine to render it kinase deficient. 
It was then FLAG-tagged at the amino terminus and cloned into the pTRE-Tight 
expression vector which harbors a tet-responsive element (www.clontech.com). This 
plasmid was electroporated into K562 cells together with the Clontech pTet-On 
Advanced plasmid, which codes for a doxycycline-regulated transactivator protein.  The 
electroporated cells were selected in G418 (800 ug/ml) for 10 days. Cell lysates for 
western blot analysis were obtained from these transfected cells as well as from the same 
cells treated for two days with doxycycline (1 ug/ml).   
 
Results 
Activated CaMKIIγ is frequently present in myeloid leukemia cell lines and primary 
AML cells.   We previously observed that CaMKIIγ is the CaMKII isoform that is 
predominantly expressed in myeloid cells (25).  The binding of Ca++/calmodulin to the 
inactive CaMKIIγ triggers autophosphorylation of this enzyme at threonine 287 leading 
to autonomous enzyme activity that is relatively independent of further Ca++/calmodulin 
regulation (17, 28, 29).    This autophosphorylated CaMKIIγ can be detected utilizing a 
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CaMKII threonine 287 phospho-specific antibody.  Utilizing this antibody on Western 
blots we observed that the autophosphorylated (activated) CaMKIIγ was invariably 
present in different human leukemia cell lines (Figure 1A). To further investigate the role 
of CaMKIIγ in the pathogenesis of human leukemia the present study focuses on the 
myeloid leukemias, and we observe that  the activated, autophosphorylated CaMKIIγ is 
also present at varying levels in the majority (11/16) of primary patient AML samples  
(Figure 1B). In contrast Western blots did not reveal any detectable autophosphorylated 
CaMKIIγ in three different normal peripheral white blood cell samples (not shown).  
    Since alternative splicing within a variable region of CaMKIIγ generates a number of 
different isoforms (30),  we determined whether the myeloid leukemia cells  exhibiting 
CaMKIIγ autophosphorylation expressed any unusual  CaMKIIγ isoform(s).   An RT-
PCR analysis utilizing primers flanking this alternatively spliced CaMKIIγ variable 
region (Figure 1C) indicated that in normal CD34+ cells as well as in  leukemia cells the 
previously described  CaMKIIγ1 and γ3 isoforms were predominantly and commonly 
expressed (Fig. 1C). In addition we determined whether the activation 
(autophosphorylation) of CaMKIIγ observed in the myeloid leukemia cell lines was 
associated with any particular mutations within the CaMKIIγ coding region in these cells. 
We PCR - amplified and sequenced the entire CaMKIIγ coding region cDNA from the 
HL60 and NB4 myeloid cell lines. The CaMKIIγ cDNA coding sequence from both these 
cell lines matched the GenBank CaMKIIγ1 and γ3 sequences. Thus the CaMKIIγ 
activation exhibited by the myeloid leukemia cells is not associated with the expression 
of any aberrantly spliced CaMKIIγ isoform(s) nor with any particular CaMKIIγ coding 
region mutation(s). 
  10 
     
Terminal differentiation/apoptosis of myeloid leukemia cell lines is associated with 
decreased CaMKIIγ activation.  All-trans retinoic acid (ATRA) induces the terminal 
granulocytic differentiation of certain myeloid leukemia cell lines including HL60 (31) 
and NB4 (32), and ATRA also induces terminal monocytic differentiation of the U937 
cell line (33). We utilized Western blots to compare CaMKIIγ expression in these cells at 
different times after this ATRA-induced terminal differentiation.  We observed in all 
three of these cell lines that ATRA-induced terminal differentiation was associated with a 
marked decrease in the levels of activated CaMKIIγ, while total CaMKIIγ levels remain 
essentially unchanged (Fig. 2A). This decrease in activated CaMKIIγ was most 
prominent 3-5 days post differentiation induction which, as previously observed (31, 32), 
is the time that these cells undergo terminal differentiation and cease to proliferate.    This 
ATRA-induced decrease in activated CaMKIIγ was not associated with any decrease in 
cellular calmodulin levels (not shown).  This decreased CaMKIIγ activation  was ATRA-
dose dependent (Fig. 2B, rows 1-3) and appeared to closely correlate with differentiation 
induction since a similar decrease was not observed in ATRA-treated HL60R cells, 
which harbor an inactivating point mutation in RARα that renders them unresponsive to 
ATRA - induced granulocytic differentiation (34) (Figure 2B, row 4). Similarly other 
myeloid leukemia cell lines that are insensitive to ATRA-induced differentiation 
including K562, KG1, THP1, and KCL22 did not exhibit any decrease in activated 
CaMKIIγ expression following ATRA induction (Figure 2B, rows 5-8). A similar marked 
decrease in activated CaMKIIγ was also observed in HL60 cells treated with phorbol 
myristate acetate (TPA), which induces terminal macrophage-like differentiation of these 
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cells (35) (Figure 2C). Similarly we observe that the terminal differentiation/apoptosis 
induced by arsenic trioxide in promyelocytic leukemia cell lines such as NB4 (36) is 
accompanied by a downregulation in phosphorylated CaMKII (Figure 2D). Thus the 
terminal differentiation of myeloid leukemia cells is associated with a marked 
downregulation of the autophosphorylated CaMKIIγ.  
     
Oncogenic bcr-abl regulates CaMKIIγ activation. In contrast to its lack of response to 
ATRA, the K562 cell line, derived from a patient with CML,  undergoes proliferative 
arrest following exposure to imatinib (gleevec), which is a potent inhibitor of the tyrosine 
kinase activity of the bcr-abl oncogene.   We observed that this imatinib -induced 
proliferation arrest is accompanied by a rapid, marked decrease in autophosphorylated 
CaMKIIγ, while there was no significant change in the total levels of CaMKIIγ following 
this imatinib exposure (Figure 3A).  
     The marked downregulation of CaMKII activation (autophosphorylation) by the bcr-
abl inhibitor, imatinib observed in K562 cells suggests that the activation of CaMKIIγ  in 
these CML cells requires bcr-abl activity. To confirm this we utilized the TonB210.1 cell 
line, which is a Baf3 - derived line whose proliferation/viability is dependent upon either 
IL-3 alone or the tet-regulated expression of  bcr-abl  (tet-on) (37). We observe in the 
TonB210.1 cells that the decreased bcr-abl expression associated with tet withdrawal is 
also accompanied by a marked and relatively rapid (within 4 hours) reduction in the 
levels of activated (autophosphorylated) CaMKII, while total CaMKIIγ levels remain 
unchanged (Figure 3B).  To determine if enhanced bcr-abl expression can initiate 
CaMKII activation, we first deprived  the IL-3 dependent TonB210.1 cells of IL-3 for 24 
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hours, which induced cell proliferative arrest associated with decreased 
autophosphorylated CaMKIIγ (Fig. 3C,  lane 1).  Treatment of these cells with tet restores 
CaMKII autophosphorylation (Fig. 3C, compare lanes 1 and 2), and this phosphorylation 
was inhibited in a dose dependent manner by the CaMK chemical inhibitors KN62 and 
KN93 (Fig. 3C, lanes 3-6), which interfere with the binding of the Ca++/calmodulin 
complex to the CaMKs (38).  In contrast this bcr-abl mediated enhancement of CaMKIIγ 
phosphorylation was not inhibited by the CaM kinase kinase (CaMKK) chemical 
inhibitor STO-609 (Fig. 3C, lanes 7-8).    Taken together these observations with the 
K562 and TonB210.1 cells indicate that oncogenic bcr-abl directly or indirectly activates 
CaMKIIγ and that this bcr-abl induced CaMKIIγ activation is dependent on 
Ca++/calmodulin binding to CaMKIIγ.   
 
Effect of inhibitors of different signal transduction pathways on CaMKIIγ 
activation.  The above observations indicate that CaMKII activation is downstream of 
bcr-abl, but we don’t know whether this oncogene directly or indirectly (through one or 
more of its downstream effectors) mediates this activation.  The molecular basis for bcr-
abl mediated cell transformation is complex and involves a number of specific 
downstream signal transduction pathways activated by bcr-abl including Stat5 (11),  
Ras/Raf1/MAPK (12),  PI3 Kinase (13) and SRC-family kinases (14). Indeed the 
cooperative activation of these pathways may be necessary for full bcr-abl mediated 
transformation (39).  We utilized specific chemical inhibitors to determine whether any 
of these signal transduction pathways downstream of bcr-abl might be involved in the 
bcr-abl mediated activation of CaMKIIγ in K562 cells.   In contrast with the gleevec 
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induced downregulation of CaMKIIγ activation  (Figure 3D, lane 17),  none of these 
chemical inhibitors reduced CaMKIIγ activation including  those which target  Jak/Stat 
(Figure 3D, lanes 3,4,16), PI3 kinase (lanes 9,10), p38 (lane 8), JNK, (lane 11), Ras/Raf/ 
MEK/ERK (lanes 6,7,12), PKC (lanes 14,15),  AMP kinase (lane 18) and SRC-family 
kinases (lane 5).    Thus the bcr-abl mediated activation of CaMKIIγ does not appear to 
involve any of the signal transduction pathways that are known downstream effectors of 
bcr-abl.   
 
 Inhibitors of CaMKII inhibit the proliferation of myeloid leukemia cell lines.  To 
determine whether inhibiting CaMKIIγ activity might have any effect on myeloid 
leukemia cell proliferation/viability, we treated K562 cells with the CaMK inhibitor 
KN93.  We found that KN93 inhibited the proliferation of K562 cells in a dose dependent 
manner (Fig. 4A, i). In contrast STO609, a potent small molecule inhibitor of CaMKinase 
Kinase (CaMKK)(40)   did not significantly inhibit K562 proliferation  nor did KN92, an 
inactive structural analog of KN62 (Fig. 4A, ii).  The KN93 induced inhibition of K562 
cell proliferation was accompanied by a reduction in the levels of the activated 
(autophosphorylated) CaMKIIγ (Fig. 5A, row 1). KN93 did not affect K562 viability, and 
no effect on the morphologic differentiation of these cells was observed. A similar KN93-
mediated inhibition of cell proliferation without any significant effect on cell viability or 
morphologic differentiation was also noted in other cultured myeloid leukemia cell lines 
including KG-1, KCL22, THP1, and Kasumi (Fig. 4B).   
      To further assess the role of CaMKIIγ in regulating myeloid leukemia cell 
proliferation, we transiently transfected K562 cells with an expression vector harboring a 
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truncated CaMKIIγ construct mutated at Lys43 , a conserved residue near the ATP-
binding site of this enzyme.  This mutation results in a ‘kinase dead’ enzyme (41),  and 
expression of this mutant inhibits endogenous CaMKII activity in a dominant negative 
manner (42). We observed a marked reduction in K562 colony formation in cells 
transfected with this mutated CaMKIIγ compared with cells transfected with vector alone 
(Fig. 4C). Thus both pharmacological and dominant negative construct inhibition of 
CaMKII results in inhibition of myeloid leukemia cell proliferation.   
      
Pharmacologic,  dominant negative or shRNA-mediated inhibition of CaMKIIγ is 
associated with the downregulation of multiple signal transduction pathways.  We 
utilized phosphorylation specific antibodies to determine whether the KN93-induced 
inhibition of K562 cell proliferation (Fig. 4A, i) was associated with any changes in 
specific phosphoprotein signal transduction pathways. As noted above KN93 treatment of 
K562 cells is associated with a time dependent reduction in CaMKIIγ phosphorylation 
(Figure 5A, row 1).   This reduction was associated with a decrease in the activation 
(phosphorylation) of a number of different critical components of signal transduction 
pathways including pMAPK p44/42 (Figure 5A, row 3), p38 (row 5), pStat3 (Y705, 
S727) (rows 10,11) and pStat5 (Y694) (row 13). These changes induced by KN93 were 
not accompanied by any change in the total levels of these phosphorylated proteins (Figs. 
5A).    These observations indicate that in K562 myeloid cells activated CaMKIIγ is 
involved in regulating the activation (phosphorylation) of MAPK p44/42, Stat3/Stat5, and 
p38.  
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     We also observe that the KN93 induced downregulation of CaMKII activation is 
associated with a marked reduction in GSK3β Ser9 phosphorylation (Fig. 5A, row 6). 
This is of particular interest since GSK3β, a serine/threonine kinase, phosphorylates and 
promotes the degradation  of β-catenin, a key component of the Wnt signaling pathway, 
which is frequently activated in myeloid  leukemia (43, 44). Since phosphorylation of 
GSK3β at Ser9 inhibits the activity of this enzyme (45), we would predict that the KN93 
induced reduction in GSK3β Ser9 phosphorylation would lead to enhanced GSK3β 
enzyme activity associated with  enhanced degradation of β-catenin.   Indeed a marked 
reduction in the expression of β-catenin is observed in the KN93 treated K562 cells (Fig. 
5B, row 3). Consistent with this, in the KN93 induced cells we also observe a reduction 
of c-myc and cyclin D1 protein levels,   both of whose expression is normally 
upregulated by β catenin (46, 47)  (Fig. 5B, rows 4,5).  
    KN93 inhibits CaMKII activity by blocking its interaction with the Ca++/calmodulin 
complex. However, this compound can potentially inhibit other enzymes activated by  
Ca++/calmodulin including CaMKI, CaMKIV, CKLiK  as well as the CaMK-kinases 
(CaMKKs). Nevertheless, several lines of evidence indicate that the effects of KN93 are 
mediated through CaMKII inhibition rather than through inhibiting any of these other 
CaMkinases. First, CaMKIV is not expressed in K562 cells (Supplemental Fig. 1A), and 
the CaMKI expressed by K562 is primarily in the inactive (unphosphorylated) form 
(Supplemental Fig. 1B). Second, there is little if any CKLiK (CaMKIδ) expression in 
K562 cells compared with other cell types (Supplemental Fig. 1C). Moreover, STO609, a 
potent small molecule inhibitor of the CaMKKs, exhibits minimal effects on K562 
proliferation (Fig. 4A, ii) indicating that neither the CaMKKs nor their downstream 
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substrate, CaMKI are the targets of KN93.  In addition we transduced a FLAG-tagged 
Lys43 mutated, dominant negative CaMKIIγ under control of a doxycycline inducible 
promoter (designated kdCaMKIIγ (Tet-on)) into K562 cells. Treatment of these cells with 
doxycycline upregulated expression of this construct (Fig. 5D, row 1, lane 4), and this 
induced expression was temporally associated with inhibition of K562 proliferation (Fig. 
5C, i) together with downregulation of the activation (phosphorylation) of the 
MAPkinase, Stat3/Stat5 and β-catenin pathways (Fig. 5D, compare lanes 3 vs.4). Finally 
we utilized an siRNA  approach to knockdown the expression of CaMKIIγ in K562 cells. 
The shRNA transduced K562 cells with reduced expression of CaMKIIγ (Figure 5D, row 
2, compare lanes 5 vs. 6) exhibited reduced cell proliferation (Fig.5C, ii), and this is 
associated with downregulation of the MAPkinase, Jak/Stat and GSK3β / β -catenin 
pathways (Figure 5D, compare lanes 5 and 6). Thus the effects of KN93 on K562 cells 
are likely mediated through its inhibitory activity on CaMKIIγ rather than through any of 
the other CaMkinases.   
    
CaMKIIγ directly phosphorylates and activates Stat3 in myeloid leukemia cells. In 
addition to tyrosine phosphorylation of Stat3 at Y705, Stat3  Ser727  phosphorylation is 
required for full Stat3 transcriptional activity (48). The activated Stat3 has oncogenic 
activity (49), and Stat 3 activation is frequently observed in myeloid leukemia cell lines 
(Fig. 6A, i) as well as myeloid leukemia patient samples (8) (Fig. 6A, ii). Our observation 
that the CaMKII inhibitor KN93 induces a decrease in Stat3 Ser727 phosphorylation 
(Fig. 5A, row 11) suggests that Stat3 may be a direct substrate of CaMKIIγ in myeloid 
leukemia cells.  Consistent with this we observe that  9/11 of the primary AML samples 
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that exhibit CaMKIIγ activation (Fig. 1B) also exhibit Stat3 Ser727 phosphorylation, 
while none of the five primary AML samples that were negative for CaMKIIγ activation 
exhibit Stat3 Ser 727 phosphorylation (Fig. 6A, ii). In addition we observe in the 
TonB210 cells that the tet-induced bcr-abl induction is associated with a marked increase 
in Stat3 Ser727 phosphorylation without any change in total Stat3 levels (Fig. 6B, 
compare lanes 1 vs 2). Moreover, this enhanced Stat3 Ser727 phosphorylation is blocked 
by KN62 or KN93 (Fig. 6B, lanes 3, 4) indicating that a CaM kinase is involved in this 
bcr-abl induced Stat3 Ser727 phosphorylation.  We also observe  that  cucurbitacin I, a  
small molecule Stat3 inhibitor,  will, as expected,  inhibit Stat3 responsive reporter 
activity, and this reporter activity is also inhibited by KN93 in a dose dependent manner 
(Fig. 6C). These latter observations indicate a functional interaction between Stat3 and 
CaMKII in myeloid leukemia cells.   
     To further assess the CaMKIIγ / Stat3 interaction we observed that in K562 cells Stat3 
co-immunoprecipitates with CaMKIIγ (Fig. 6D, i). Moreover, CaMKIIγ phosphorylates 
Stat3 at Ser727 both in vitro (Fig. 6D, ii) and in vivo (Fig. 6D, iii). Together these 
observations suggest that  Stat3 is likely a direct substrate of CaMKIIγ in myeloid 
leukemia cells and that the KN93 induced inhibition of K562 cell proliferation (Fig. 4A)  
may be  mediated, at least in part, through its inhibition of Stat3 Ser727 phosphorylation.    
 
Discussion 
     The CaM kinases (CaMKs) are major targets of Ca++ regulated physiological events, 
and the role of a particular CaMK, (i.e. CaMKII), in regulating both neuronal and cardiac 
muscle cell development and activity has been well established.  Our present study 
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defines a novel and critical role for the activated (autophosphorylated) CaMKII 
(CaMKIIγ) in regulating the proliferation of myeloid leukemia cells.  Indeed we observe 
that relatively high amounts of the autophosphorylated CaMKIIγ are invariably present in 
myeloid leukemia cell lines, and this activation is also observed in the majority of 
primary patient AML samples.    In  different in vitro models of myeloid leukemia cell 
terminal differentiation /growth arrest  including those triggered by ATRA, TPA, arsenic 
trioxide or gleevec, the loss of proliferation of the induced leukemia cells is accompanied 
by a marked reduction in CaMKIIγ activation. This marked downregulation of CaMKIIγ 
activation likely directly contributes to the loss of leukemia cell proliferative capacity 
since we observe that both pharmacologic, dominant negative and shRNA-mediated 
inhibition of CaMKII expression / activity inhibits myeloid leukemia cell proliferation. 
Moreover, we observe that CaMKIIγ directly or indirectly regulates multiple signaling 
pathways previously implicated in leukemia cell proliferation including the MAPKinase, 
Jak/Stat and GSK3β / β-catenin pathways.   
        What are the molecular events that trigger and maintain CaMKIIγ constitutive 
activation (autophosphorylation) in the myeloid leukemia cell lines and primary patient 
AML samples?  The myeloid leukemias are remarkably heterogenous, and diverse 
molecular events may trigger CaMKIIγ activation in these leukemias. Our observations in 
cell lines driven by oncogenic bcr-abl indicate that CaMKII activation is downstream of  
bcr-abl  but  is not regulated  by other bcr-abl  activated signal transduction events 
involving  the MAP kinase, Jak/Stat, SRC - related kinase or PI3 kinase pathways (Fig. 
3D).  The primary trigger of CaMKII activation is its binding to Ca++/calmodulin, whose 
levels are regulated by intracellular Ca++ concentration. Our observations in TonB210.1 
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cells suggest that the bcr-abl mediated CaMKII activation is dependent, at least in part,  
upon Ca++/calmodulin binding to CaMKII since this bcr-abl induced activation is 
inhibited by KN62 or KN93,  which block Ca++/calmodulin binding to CaMKII (Fig. 3C). 
This suggests that bcr-abl might regulate intracellular Ca++/calmodulin levels, and this 
would likely involve the regulation by this oncogene of intracellular Ca++ concentration. 
Nevertheless how bcr-abl might regulate intracellular Ca++ levels and Ca++/calmodulin 
activity is currently unknown.   
     Closely related to the question of how CaMKIIγ is activated in myeloid leukemia cells 
is how this enzyme becomes inactivated (dephosphorylated) during terminal myeloid 
differentiation/growth arrest (Fig. 2). Indeed we observe a prominent decrease in 
CaMKIIγ activation during ATRA-induced terminal granulocytic differentiation of 
myeloid leukemia cells and also note that normal granulocytes harbor relatively low 
levels of the activated CaMKIIγ.  This terminal myeloid differentiation is not associated 
with any decrease in total cell calmodulin concentration to account for the reduced 
CaMKIIγ activity.  One possibility to explain this downregulation of CaMKIIγ 
autophosphorylation is that myeloid differentiation is accompanied by changes in Ca++ 
channel activity with an associated decrease in intracellular Ca++ concentration that 
reduces the Ca++/calmodulin activation of CaMKII. Another possibility is that an increase 
in phosphatase activity that targets the activated (autophosphorylated) CaMKIIγ 
accompanies myeloid differentiation. Consistent with this latter possibility we have 
observed that PP2A, a phosphatase known to dephosphorylate CaMKII in neuronal cells 
(50),  coimmunoprecipitates  with CaMKIIγ in myeloid cells (not shown). However the 
levels of PP2A do not appear to change during myeloid leukemia cell differentiation (not 
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shown), and whether the phosphatase activity that specifically targets the activated 
(autophosphorylated) CaMKIIγ  is developmentally regulated during myeloid 
differentiation is presently unknown.   
     What are the critical substrates of CaMKIIγ that are involved in regulating myeloid 
leukemia cell proliferation?  In HeLa cells CaMKII phosphorylation of the cdc25 
phosphatase is associated with cdc2 activation and enhanced G2/M transition (51). 
Moreover, the localization of CaMKII to the mammalian midbody also suggests a role for 
this enzyme in regulating cytokinesis (52). We have previously observed that CaMKIIγ 
directly phosphorylates and inhibits the transcriptional activity of RARα, which is an 
important regulator of the terminal differentiation of certain myeloid leukemia cells (25).  
Our present study indicates that Stat3, which exhibits oncogenic activity (49), is directly 
phosphorylated by CaMKIIγ,  and this phosphorylation enhances Stat3 transcriptional 
activity (Fig. 6).  We also observe that CaMKIIγ directly or indirectly promotes the 
inhibitory phosphorylation of GSK3β, an enzyme which normally downregulates the 
expression of cell growth/proliferation factors including β-catenin, c-myc and cyclinD1 
(Fig. 5B). Thus CaMKII activity appears to orchestrate a complex, interacting network of 
molecular events that are involved in regulating the proliferation of myeloid leukemia 
cells.  
 
    Our observation that CaMKIIγ is an important regulator of multiple phosphoprotein 
signaling networks regulating myeloid leukemia cell proliferation suggests that targeting  
this enzyme might be of therapeutic benefit in human myeloid leukemia. Indeed we 
reproducibly observe an inhibition of myeloid leukemia cell proliferation triggered by 
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KN93, a small molecule inhibitor of CaMKII.  However, the CaMKII pharmacological 
inhibitors have significant limitations. These compounds inhibit CaMKII activity by 
interfering with their binding to the Ca++/calmodulin complex. However, once CaMKII 
has become activated (autophosphorylated) its dependence upon further Ca++/calmodulin 
binding is markedly diminished (18). Thus these compounds exert considerably less 
inhibition on CaMKII once it has become activated (autophosphorylated).  An “ideal” 
CaMKIIγ inhibitor would be a small molecule which would directly inhibit the activated 
CaMKIIγ by directly targeting its ATP binding pocket.  Such a CaMKIIγ inhibitor has 
not been identified, but we would predict that it would exert much greater activity in 
inhibiting leukemia cell proliferation than KN93 and might be of significant value in the 
targeted therapy of myeloid leukemia.  
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Figure Legends 
 
Figure 1. CaMKIIγ activation in myeloid leukemia cells. 
A). Cell lysates from the indicated human leukemia cell lines were subjected to Western 
blots utilizing the indicated CaMKII antibodies. Antibodies to the catalytic subunit of 
PP2A (PP2Ac) serve as a loading control.  
B). Cell lysates from primary AML samples were subjected to Western blots utilizing the 
indicated CaMKII antibodies. Antibodies to PP2Ac serve as a loading control.  
C) RT-PCR was performed on RNA extracted from the indicated leukemia cell lines and 
normal CD34+ cells and the products were displayed on an agarose gel.    The location of 
the sense (S) and antisense (AS) primers in relationship to the catalytic, regulatory, 
variable and association domains of the human CaMKIIγ coding sequence are indicated.  
 
Figure 2. Terminal differentiation/apoptosis of myeloid leukemia cells is associated 
with decreased CaMKIIγ activation.  
A). Lysates from the HL60, NB4 and U937 myeloid cell lines treated with ATRA (1μM) 
for the indicated period of time were subjected to Western blots.  
B).  Lysates from the indicated myeloid cell lines treated  for five days with the indicated 
concentration of ATRA  were subjected to Western blots.   
C). Lysates from HL60 cells treated with TPA (0.1 μM) for the indicated time were 
subjected to Western blots.  
D). Lysates from NB4 cells treated with arsenic trioxide (1 uM) for the indicated time  
were subjected to Western blots.  
 
Figure 3. Inhibiting bcr-abl activity/expression inhibits CaMKIIγ activation.  
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A). Lysates from K562 cells undergoing growth arrest following treatment with gleevec 
(5uM)  for the indicated times were subjected to Western blots.  
B). Lysates from TonB210.1 cells depleted of doxycycline for the indicated period of 
time were subjected to Western blots.   
C). IL-3 dependent TonB210.1 cells were deprived of IL-3 for 24 hours (lane 1).  The 
cells were then treated with the indicated compounds simultaneously with the addition of 
doxycycline (lanes 2-8).   After 24 hours cell lysates were harvested and subjected to 
Western blots with the indicated CaMKII antibodies.  
D). K562 cells were cultured for 48 hours with the indicated chemical inhibitors of 
specific signal transduction pathways.  Cell lysates were harvested and subjected to 
Western blot analysis.  
 
Figure 4. CaMKII inhibitors inhibit myeloid leukemia cell proliferation.  
A). K562 cells were seeded in liquid suspension culture at 5 X 104 cells/ml in the 
presence or absence of the indicated concentration of compounds, and cell counts were 
obtained at the indicated time.   
B).  The indicated myeloid leukemia cell lines were seeded in liquid suspension culture at 
5 X 104 cells/ml in the presence or absence of KN93, and cell counts obtained at the 
indicated time. 
 C). K562 cells were electroporated with the LXSN expression vector harboring the 
kinase dead, Lys43 mutated, truncated CaMKII construct (kdCaMKII) as well as with the 
control (empty) LXSN vector. The electroporated cells were diluted into 96 well plates in 
liquid suspension culture in the presence of G418 (1 mg/ml). Following eight days of 
culture the total number of discrete, actively proliferating G418 resistant colonies within  
individual wells was determined.    
 
Figure 5. CaMKII regulates multiple signal transduction pathways in myeloid cells.  
(A,B). Lysates from K562 cells cultured for the indicated time in KN93 were subjected to 
Western blots. (C) The K562 cells transduced as described in Materials and Methods with 
either (i) the doxycycline (DOX) inducible expression vector / transactivator harboring 
the full length,  Lys43 mutated,  kinase dead CaMKIIγ (kdCaMKIIγ (Tet-on) )   or (ii) the 
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CaMKII shRNA generating plasmids,  were cultured in liquid suspension in the presence 
or absence of DOX as indicated, and cell counts obtained after 48 hours.  (D) Lysates 
from K562 cells transduced with the indicated vectors were subjected to Western blots 
utilizing the indicated antibodies. For lanes 2 and 4 doxycycline (DOX) treatment was for 
two days.  
 
Figure 6.  Stat3 is directly phosphorylated and activated by CaMKIIγ at Ser727.  
A, i). Cell lysates from the indicated human leukemia cell lines were subjected to 
Western blots utilizing the indicated Stat3 antibodies. 
ii). Cell lysates from the same primary AML samples depicted in Fig. 1B were subjected 
to Western blots utilizing the indicated Stat3 antibodies. 
B). The IL-3 dependent TonB210.1 cells were deprived of IL-3 for 24 hours. The cells 
were then treated with the indicated compounds immediately prior to the addition of 
doxycycline.  After an additional 24 hours cell lysates were harvested and subjected to 
Western blots with the indicated Stat3 antibodies.  
C). K562 cells were electroporated with a luciferase reporter driven by a Stat3 response 
element. The indicated concentrations of KN93 and the Stat 3 inhibitor, cucurbitacin I,  
were added and relative luciferase activity determined on cell lysates following 48 hours 
of culture. 
D, i) K562 cell lysates were immunoprecipitated with control IgG or a Stat3 antibody. 
The immunoprecipitates were then subjected to Western blot analysis with the indicated 
antibodies.   
ii, ) A bacterial - expressed GST-Stat3 fusion protein was incubated in vitro with 
CaMKIIγ that had been immunoprecipitated from HL60 cells. Western blots were then 
performed on the reaction mixtures utilizing the indicated Stat3 antibodies.  
iii, ). NIH3T3 cells were transfected with the empty LXSN expression vector (lane 1), the 
same vector harboring the coding sequences of a constitutively active (ca) CaMKIIγ (lane 
2), or vector harboring the kinase dead (kd) CaMKIIγ (lane 3). After 48 hours Western 
blots were performed on cell lysates utilizing the indicated Stat3 antibodies.   
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Figure 4. 
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Figure 6 
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Supplemental Figure 1.  
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Supplemental Figure 1.  (A,B) Western blots were performed on cell lysates from the 
indicated cell lines utilizing the indicated antibodies. (C) RT-PCR was performed on 
RNA from the indicated cell lines. The experimental protocol together with the primer 
sequences are available on request.  
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